These are the posts from the How we think section that have been tagged with Neurology.
To see all tags used in our posts, click here.
|27th September 2019
Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. But if a new therapy entered the market today, would healthcare systems be ready for it? Customer Experience Consultant Fadi Haddadeen explores this issue by mapping the patient and neurologist journeys.
|16th July 2019
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
|7th June 2019
Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the importance of a holistic approach to MS and why digital technology is the future of effective MS care.
|25th April 2019
Patient advocate Trishna Bharadia explains why shared decision making is crucial for ensuring multiple sclerosis patients feel heard and empowered
|6th February 2019
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.
|23rd January 2019
Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.
|11th December 2018
Blue Latitude Health sits down with key opinion leader and specialist neurologist Dr Timothy Vollmer to better understand the paradigm shift in MS treatment. He explains the challenges neurologists face when making treatment decisions, and why patients need to be treated with more efficacious drugs earlier on.
|3rd December 2018
Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can unite to improve quality of life for MS patients today, and why her diagnosis isn’t stopping her achieving her goals.
|2nd September 2016
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.